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he Role of the
ulmonary Vasculature
n Heart Failure With
reserved Ejection Fraction*
regory D. Lewis, MD
oston, Massachusetts
ulmonary hypertension (PH) is present in a broad spec-
rum of systemic diseases (1). Despite an established World
ealth Organization (WHO) classification system (1) and
n expanding armamentarium of available pharmacothera-
ies (2), the prevalence of PH in the general population
emains unknown. Pulmonary hypertension has been re-
orted in specific patient populations with variable fre-
uency (i.e., portal hypertension: 0.6% to 2% [3], systemic
clerosis: 12% to 33% [4,5], obstructive sleep apnea: 15% to
0% [6]), but is particularly common in heart failure with
educed left ventricular ejection fraction (68% to 76% [7,8])
nd mitral stenosis (9).
See page 1119
In this issue of the Journal, Lam et al. (10) provide the first
opulation-based report of the prevalence, severity, and prog-
ostic implications of PH in heart failure (HF) with preserved
eft ventricular ejection fraction (HFpEF). The investigators
re to be commended for including consecutive patients with
FpEF (n  222) and appropriate hypertensive control
ubjects (n  719) from the same community, with complete
ollow-up for a median of 2.8 years. Pulmonary hypertension,
s defined by echocardiogram-derived pulmonary artery sys-
olic pressure (PASP) 35 mm Hg (11), was present in 83%
f patients with HFpEF and only 8% of controls. In addition
o the excellent discriminatory power of PH for the diagnosis
f HFpEF, PASP was the only echocardiogram-derived pa-
ameter in HFpEF that predicted mortality in this cohort.
Requisite fulfillment of Framingham Heart Study criteria
or HF (12) within 1 day of study (13) and frequent
ospitalization at the time of echocardiogram likely led to
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Cardiology Division of the Department of Medicine, Massachusetts
eneral Hospital, Harvard Medical School, Boston, Massachusetts.verestimation of HFpEF patients’ average ambulatory
ASP, and therefore may have resulted in a higher discrim-
natory capacity of PASP than if it were measured in stable
utpatients. In fact, the median PASP of 48 mm Hg in this
tudy was highly consistent with the median PASP of 47
m Hg reported in a case series of similar patients hospi-
alized for decompensated HFpEF (14).
However, the extent to which PASP increases with HF
xacerbations may in fact be modest. Recently reported
xperience with permanent implantable hemodynamic
onitoring devices in patients with HFpEF enrolled in the
OMPASS (Chronicle Offers Management to Patients
ith Advanced Signs and Symptoms of Heart Failure) study
ndicated that median daily right ventricular systolic pres-
ure increased by only 8% (from 50  10 mm Hg to 54 
2 mm Hg, p  0.001) between baseline evaluation, 7
eeks before HF exacerbation, and 1 day before urgent
resentation for hypervolemia (15). Further investigation is
eeded to establish the temporal stability of repeated echocar-
iographic PASP measurements in HFpEF. If low biologic
ariance in resting PASP is confirmed, it will add to the
tility of this measurement in the diagnosis and treatment of
FpEF.
The way in which HFpEF is defined may also influence
he reported burden of PH in this patient population. The
se of Framingham Heart Study criteria to define HFpEF
an lend itself to inclusion of patients with WHO classes 1,
, 4, and 5 PH, who may manifest Framingham Heart
tudy criteria (i.e., jugular venous distention, hepatojugular
eflux, lower-extremity edema, or radiographic cardiomegaly)
ecause of symptomatic right HF, on account of pulmonary
rterial hypertension, instead of PH secondary to left
entricular diastolic dysfunction (LVSD). The investigators
ppropriately conducted subgroup analysis to exclude
hronic obstructive pulmonary disease and definitive cases in
hich alternative causes of PH were likely, which did not
lter their conclusions. However, in further mechanistic
tudies to characterize PH in HFpEF, it will be important
o narrowly define HFpEF and to consider independent
rocesses influencing pulmonary arterial and right ventric-
lar function.
The use of echocardiography to assess PASP and pulmo-
ary capillary wedge pressure (PCWP) limits precision
16,17) and relies on a discernable tricuspid regurgitant jet
hat was absent in 13% of patients with HFpEF in this
tudy. Nonetheless, one of the most important findings of
his article was the significant pre-capillary, pulmonary
rterial contribution to PH in HFpEF. After adjusting for
CWP, PASP remained significantly higher in HFpEF
han in hypertensive controls. The investigators point out a
ignificant relationship between PCWP and PASP (r 
.21, p  0.007), consistent with a passive contribution of
ulmonary venous hypertension to increased PASP in
FpEF. However, the weakness of this relationship is striking
nd indicates marked variability in PASP at a given left-sided
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Pulmonary Vasculature in HFpEF March 31, 2009:1127–9lling pressure in HFpEF (see Fig. 2 in Lam et al. [10]). This
nding, coupled with the evident prognostic importance of PH
n HFpEF, opens the door to investigation of genetic, envi-
onmental, and biochemical factors mediating such heteroge-
eity in pre-capillary PH in HFpEF.
Disproportionate increases in pulmonary arterial pressure
PAP) relative to left-sided filling pressures in HFpEF are
ot unexpected based on our knowledge of other left-sided
onditions such as LVSD. Butler et al. (8) showed that
levated pulmonary vascular resistance (PVR, as defined by
mean PAP – PCWP]/cardiac output), reflecting pulmo-
ary arterial hypertension superimposed on pulmonary ve-
ous hypertension, was present in 72% of patients with New
ork Heart Association functional class II to IV with
hronic LVSD (8). Pre-capillary PH in LVSD is mediated
y hypertension characterized by insensitivity to vasodilators
cting through nitric oxide, endothelin, or prostaglandin
ignaling pathways (18), and vascular remodeling consisting
f abnormal thickening of arterial neointima and medial
ypertrophy with notable absence of plexiform lesions (19).
ariable success in reducing fixed pulmonary hypertension
as been reported with strategies to improve left ventricular
erformance with inotropes such as milrinone and dobut-
mine (20), vasodilators such as nesiritide (21), and left
entricular assist devices (22).
Clinical consequences of developing pre-capillary PH are
ignificant. In LVSD, as in other World Health Organiza-
ion classes of pulmonary arterial hypertension, elevated
AP and PVR potently predict morbidity and mortality (7).
n addition, there is a strong inverse relationship between
VR and exercise capacity as measured by peak VO2 (8,23).
inally, pre-capillary PH is closely associated with ineffi-
ient ventilation (high VE/VCO2 slope) (24), which contrib-
tes to hyperpnea and dyspnea on exertion and portends a
oor prognosis (25).
Hence, it is intriguing to postulate that in HFpEF, the
ropensity for individuals to develop pre-capillary PH in
esponse to elevated filling pressures may contribute to the
evelopment of signs and symptoms of HF before left
entricular remodeling results in diminution of left ventric-
lar ejection fraction. At the very least, the discriminatory
ower of elevated PASP in HFpEF reflects the fact that
ASP is an integrative barometer of both left-sided filling
ressures and pulmonary vascular tone.
Invasive studies are needed to precisely quantify transpul-
onary gradients in HFpEF and to elucidate mediators of
re-capillary PH in HFpEF. Unanswered questions include
hether there is differential expression of genes or biochem-
cal profiles shown to mediate pulmonary arterial hyperten-
ion (26) in HFpEF and whether subclassification of sec-
ndary PH in HFpEF based on responsiveness of the
ulmonary vasculature to exercise or vasodilator treatments
redicts responsiveness to pulmonary vasodilator therapies
n HFpEF.
In light of the findings of Lam et al. (10) coupled with
isappointing results from recent pharmacotherapy trials inFpEF (27,28), it is attractive to consider pharmacotherapy
irected at pre-capillary PH in HFpEF. Pulmonary vaso-
ilation poses the risk of increasing transit of blood to the
eft atrium and thereby dangerously elevating left-sided
lling pressures in left heart disease. However, the phos-
hodiesterase 5 inhibitor sildenafil has recently been shown
o improve exercise capacity and ventilatory efficiency in
VSD (29–31). The magnitude of improvement in peak
O2 with sildenafil treatment was proportionate to reduc-
ion in exercise PVR, and no increase in rest or exercise
CWP was observed compared with placebo (30). The
ecently initiated RELAX (Phosphodiesterase-5 Inhibition
o Improve Clinical Status and Exercise Capacity in Dia-
tolic Heart Failure) trial will test the hypothesis that
hosphodiesterase 5 inhibition improves exercise capacity
nd quality of life in patients with HFpEF.
In summary, Lam et al. (10) provide strong evidence that
H is common in HFpEF and that noninvasive measure-
ent of PASP may prove useful in diagnosing HFpEF and
n selecting patients at increased risks for adverse events.
urther studies are needed to determine mediators of
econdary PH in HFpEF and to test the hypothesis that PH
s a potential target for therapeutic intervention.
eprint requests and correspondence: Dr. Gregory D. Lewis,
assachusetts General Hospital, Bigelow 800, 55 Fruit Street,
oston, Massachusetts 02114. E-mail: glewis@partners.org.
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